rospective mono-center experience of the Seoul Children Hospital reported 6 patients treated with relapse-free survival achieved in 5.
5 Taking these cases together with earlier case reports, 2,4,6-10 far less than 100 cases of PCNSL in children and adolescents have been published so far.
In the current study of the population-based NHL-BFM data (Berlin-Frankfurt-Muenster), the frequency, clinical characteristics, diagnostic difficulties, treatment and outcome of 17 pediatric PCNSL patients are discussed. All patients were uniformly diagnosed and treated according to NHL-BFM protocols. The study aims to add relevant information to the ongoing discussion concerning optimal treatment. Also, the description of the prolonged and difficult diagnosis and differential diagnosis procedures in the current report might raise awareness of pediatric patients with PCNSL.
Children and adolescents diagnosed with any subtype of NHL were registered with the NHL-BFM-center after patients and/or guardians gave informed consent. Standard haematologica 2014; 99:e238 no  1  yes  no  yes  PTCL  alive#  4 F 15,2 no  no  201  15  20-39%  no  multiple  no  yes  yes B-NHL nfc  alive  5 M 15,3 no  no  250  8  40-59%  yes  208  3  yes  yes  yes  Burkitt  alive  6 M 7,8  no  no  257  20  <20%  yes  76 multiple yes  no  no  ALCL  alive  7 F 12,6 no  no  110  4  60-79%  yes  4  1  yes  no  no  ALCL  alive  8 M 17,9 no  no  171  12  40-59%  no  multiple yes  no  yes  ALCL  alive  9 M 14,0 no  no  151  2  >=80%  no  1  no  yes  no B-NHL nfc  alive  10 M 14,1 no  no  235  12  20-39%  yes  277  2  no  yes  yes  DLBCL  alive  11 M 9,6 yes   $   no  273  3  40-59%  no  1  yes  no  no  DLBCL died from  graft or B-NHL BFM04 13 protocols. Institutional review board approvals were obtained before patients were included in the study.
LETTERS TO THE EDITOR
For statistical analyses, differences between subgroups were examined by c 2 test or Fisher's exact test. Probability of survival (pOS) was calculated from diagnosis to first event (death, progression/relapse/non-response, second malignancy) or to last follow up using the Kaplan-Meier method. Differences were compared using the log rank test, and the standard error (SE) was calculated according to Greenwood. Statistical analysis was performed using the SAS program v.9.13 (SAS Institute Inc., Cary, NC, USA).
Among 3740 pediatric or adolescent NHL patients registered between 1990 and 2011, 17 patients with PCNSL were identified: 12 immunocompetent and 5 immunocompromised. Median age was 13.3 years (range 1.3-17.9 years). The histological diagnosis was peripheral T-cell lymphoma (PTCL) in one patient, anaplastic large cell lymphoma (ALCL) in 5 patients, and mature aggressive B-cell lymphoma (B-NHL) in 11 patients (Figure 1 Presenting symptoms were often symptoms of increased intracranial pressure with headache (53%), nausea (53%), and vomiting (47%) or ataxia (41%), and symptoms of cranial nerve disorders (59%). Median interval between onset of symptoms and the diagnostic procedure that led to the diagnosis of PCNSL was eight weeks (range 2-20 weeks). Seven patients were treated for meningitis/encephalitis and one patient was treated for multiple sclerosis. Nonresponse to this anti-infectious treatment resulted in the tumor biopsy that allowed PCNSL diagnosis in these 8 patients. At the time of PCNSL diagnosis, 7 patients presented with severe neurological complications such as hemiparesis (n=1), seizures (n=3), incomplete paraparesis (n=2), and somnolence requiring immediate trepanation (n=1). Five patients suffered from underlying immunodeficiency or immunomodulation (Table 1) .
Patients were treated according to NHL-BFM protocols with pre-phase followed by six 5-day courses of chemotherapy (summarized in Figure 2A ).
11-13 ALCL patients received cranial radiotherapy (CRT) of 24 Gy after chemotherapy.
With a median follow up of 7.5 years (range 2.4-12.1 years), the 3-year probability of overall survival (OS) of all 17 PCNSL patients was 63+12% and 92+8% for the 12 immunocompetent patients (Figure 2 ). All 5 patients with underlying diseases died 0, 1, 4, 16 and 31 months after start of treatment (Table 1) . Among the 12 immunocompetent patients, one event was reported in an ALCL patient who suffered leptomeningeal relapse nine weeks after end of treatment and died of lymphoma progression (Patient 2).
Concerning neurological outcome and late effects, 2 patients suffered from reduced visual acuity due to atrophy of the optical nerve related to prolonged increased intracranial pressure (Patients 6 and 10). One patient suffered from epilepsy after end of treatment (Patient 6), and one patient suffered from panhypopituitarism after surgical lymphoma resection localized in the suprasellar midline (Patient 5). In the remaining 8 patients alive, no relevant neurological deficit was reported 6, 21, 29, 41, 48, 80, 84 and 84 months after start of treatment of PCNSL.
Primary central nervous system lymphoma represents a rare NHL-subtype in adults and children and is associated with a poor prognosis. The current PCNSL series of the NHL-BFM-group represents the largest series of uniformly diagnosed and treated pediatric PCNSL patients. Patients' characteristics and histological diagnoses of the NHL-BFM cohort are similar to earlier reports except for the initial serum LDH levels, which are normal for the majority of NHL-BFM patients. This is in contrast to the IPCG cohort with elevated LDH levels 53% of 17 cases with available data. 3 The detailed chart review of the NHL-BFM PCNSL patients documents for the first time the complicated medical histories until a definite diagnosis in pediatric PCNSL patients can be made. The onset of seizures leads to the shortest intervals between first symptoms and a definite diagnosis. The diagnosis of PCNSL is complicated, especially in adolescents with non-specific symptoms. Although a rare disease, PCNSL should be considered in healthy children and adolescents with non-specific neurological symptoms. The performance status (PS) at diagnosis has been reported as prognostic factor. 3 The current NHL-BFM data cannot support an increase or decrease of treatment intensity according to general condition at diagnosis. Any other evaluation of reported prognostic parameters, such as age, LDH, or cortical versus deep brain lesions, could not be tested in the NH-BFM series as only one immunocompetent patient suffered relapse.
All 5 NHL-BFM patients with severe underlying diseases died due to toxicity or complications of the underlying disease (n=4) and lymphoma progression without PCNSL treatment (n=1). Abla reported 4 cases of PCNSL with immunodeficiency of whom one died of infectious complications after treatment. 4 The IPCG cohort included 3 patients with immunodeficiency but outcome is not specified. 3 In addition, individual cases of pediatric PCNSL patients with immunodeficiency were reported. 2, 7 In conclusion, the number of pediatric PCNSL patients with immunodeficiency is limited and the individual medical course variable. However, the NHL-BFM-group will critically discuss treatment recommendations when consulted for PCNSL patients with immunodeficiency taking into account the experiences and guidelines for NHL-treatment in patients with chromosomal instability syndromes.
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In the NHL-BFM series, only one out of the 16 patients treated for PCNSL suffered relapse. In spite of the small number of patients, disease control of PCNSL treated according to NHL-BFM protocols for CNS-positive NHL seems comparable to that of systemic NHL with CNS involvement. 15 The relapse rate in the current NHL-BFM series is remarkably lower than in the IPCG cohort with 10 relapses in 29 patients (34%), all suffering from isolated CNS relapse.
3 The 2-year progression-free survival of 61% and the 3-year OS of 82% for the IPCG cohort might indicate insufficient front-line treatment, at least for a subset of patients. In contrast, the intensive NHL-BFM treatment might reduce the rate of relapse but also selects for resistant disease at relapse. This hypothesis is supported by a recently reported series of 6 pediatric PCNSL patients treated with intensive protocols LMB-FAB96 in 5 patients and CCG-106B in one patient, and the observation of only one relapse but resistant disease at the time of relapse.
5
In the current series, only ALCL patients, but not B-NHL patients, received cranial radiotherapy per protocol. Interestingly, the only relapse occurred in one of the 5 ALCL patients with none in the B-NHL patients. This supports the conclusion of the above-mentioned report that stated that PCNSL of B-NHL subtype can be successfully treated without irradiation.
